Literature DB >> 23591553

Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome.

Roberto Cilia1, Chiara Siri, Margherita Canesi, Anna Lena Zecchinelli, Danilo De Gaspari, Francesca Natuzzi, Silvana Tesei, Nicoletta Meucci, Claudio Bruno Mariani, Giorgio Sacilotto, Michela Zini, Claudio Ruffmann, Gianni Pezzoli.   

Abstract

OBJECTIVE: Dopamine dysregulation syndrome (DDS) refers to a compulsive pattern of dopaminergic drug misuse complicating Parkinson's disease (PD). To date, few data are available on DDS risk factors, cognitive profile and long-term outcome.
METHODS: In this retrospective case-control study, consecutive PD outpatients fulfilling criteria for DDS were assessed over a 6-year period (2005-2011). They were compared with 70 PD cases matched for age at onset, gender and disease duration, and with 1281 subjects with motor fluctuations and dyskinesias. DDS patients and matched controls underwent extensive neuropsychological assessment. Strategies for DDS patients management and the outcome at the last follow-up visit were recorded.
RESULTS: Thirty-five patients with DDS were identified, reporting history of depression, family history of PD and drug abuse, greater difference between 'Off' versus 'On' motor symptoms compared to age-matched controls. They had younger age at onset (but not any gender difference) compared to general PD population. Cognitive profile of DDS did not show major abnormalities, including executive functions. DDS patients have been followed up for 3.2±2.1 years and remission was recorded in 40% of cases. Negative DDS outcome was significantly associated with poor caregiver supervision. Sustained remission occurred more commonly on clozapine and on duodenal levodopa infusion and subthalamic nucleus deep brain stimulation (STN-DBS) than on apomorphine pump treatment.
CONCLUSIONS: Clinicians should be aware of risk factors predisposing to DDS. Duodenal levodopa infusion and, less consistently, STN-DBS were more commonly associated with DDS remission. Effective caregiving plays a key role in long-term behavioural outcome.

Entities:  

Keywords:  BEHAVIOURAL DISORDER; CLINICAL NEUROLOGY; MOVEMENT DISORDERS; NEUROPSYCHIATRY; PARKINSON'S DISEASE

Mesh:

Substances:

Year:  2013        PMID: 23591553     DOI: 10.1136/jnnp-2012-303988

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  13 in total

Review 1.  New pharmacological and neuromodulation approaches for impulsive-compulsive behaviors in Parkinson's disease.

Authors:  Giacomo Grassi; Giovanni Albani; Federica Terenzi; Lorenzo Razzolini; Silvia Ramat
Journal:  Neurol Sci       Date:  2021-04-14       Impact factor: 3.307

Review 2.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

3.  Opposing effects of dopamine D1- and D2-like agonists on intracranial self-stimulation in male rats.

Authors:  Matthew F Lazenka; Luke P Legakis; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2016-03-17       Impact factor: 3.157

4.  Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care.

Authors:  Jacob Taylor; William S Anderson; Jason Brandt; Zoltan Mari; Gregory M Pontone
Journal:  Am J Geriatr Psychiatry       Date:  2016-09-03       Impact factor: 4.105

5.  Delusions in Parkinson's Disease: A Systematic Review of Published Cases.

Authors:  Nicola Warren; Cullen O'Gorman; Zena Hume; Steve Kisely; Dan Siskind
Journal:  Neuropsychol Rev       Date:  2018-08-02       Impact factor: 7.444

Review 6.  Impulse control disorders in Parkinson's disease: an overview from neurobiology to treatment.

Authors:  Emke Maréchal; Benjamin Denoiseux; Ellen Thys; David Crosiers; Barbara Pickut; Patrick Cras
Journal:  J Neurol       Date:  2014-05-14       Impact factor: 4.849

7.  Relationship of Movement Disorders Society-Unified Parkinson's Disease Rating Scale Nonmotor Symptoms to Cognitive Functioning in Patients with Parkinson's Disease.

Authors:  Bryan A Bernard; Danielle Carns; Glenn T Stebbins; Jennifer G Goldman; Christopher G Goetz
Journal:  Mov Disord Clin Pract       Date:  2020-02-12

8.  The Outcome of Dopamine Dysregulation Syndrome in Parkinson's Disease: A Retrospective Postmortem Study.

Authors:  Pedro Barbosa; Atbin Djamshidian; Andrew J Lees; Thomas T Warner
Journal:  Mov Disord Clin Pract       Date:  2018-10-04

Review 9.  Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease.

Authors:  Robert S Eisinger; Adolfo Ramirez-Zamora; Samuel Carbunaru; Brandon Ptak; Zhongxing Peng-Chen; Michael S Okun; Aysegul Gunduz
Journal:  Front Neurol       Date:  2019-02-26       Impact factor: 4.003

Review 10.  Challenges in PD Patient Management After DBS: A Pragmatic Review.

Authors:  Malco Rossi; Verónica Bruno; Julieta Arena; Ángel Cammarota; Marcelo Merello
Journal:  Mov Disord Clin Pract       Date:  2018-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.